Peptide Therapy Near Me: How to Find a Peptide Provider

Key Takeaways

• Regulatory Status: Peptide therapy requires a prescription from a licensed U.S. provider for any compound with therapeutic intent. As of April 2026, access to compounded peptides depends on specific compound classification — Category 1 substances (FDA's interim-list bulk drug substances eligible for 503A compounding while under review), including sermorelin, may be compounded from bulk at a licensed 503A pharmacy pursuant to a patient-specific prescription. No FDA-approved sermorelin product is currently marketed in the U.S.; all U.S. sermorelin access is via 503A compounding. Following the February 2026 FDA determination, BPC-157 and TB-500 are not eligible for 503A compounding; no lawful U.S. compounding pathway currently exists for these compounds.
• Research Stage: Evidence quality varies dramatically by compound — from Phase 3 RCT data for FDA-approved GLP-1 agonists to primarily preclinical animal data for research peptides commonly offered by local wellness clinics.
• Availability: Available through licensed in-person providers and telehealth platforms operating with the same clinical standard; also widely marketed through wellness clinics with highly variable quality.
• How it works: Peptide therapies bind specific receptors to trigger targeted biological cascades in metabolism, hormone regulation, and tissue function.
• What the evidence shows: Clinical trial evidence is most extensive for FDA-approved GLP-1 receptor agonists for weight management and for tesamorelin within its approved HIV-lipodystrophy indication; evidence is substantially weaker for most compounds offered outside approved indications.

"Peptide therapy" is offered across a broad category of provider types: hospital-affiliated endocrinology practices, concierge medicine clinics, functional medicine offices, weight loss med spas, and telehealth platforms that operate nationally. These provider types share a common label while differing substantially in clinical standards, compound sourcing, laboratory oversight, and the evidence basis for what they prescribe. A 2018 review by Lau and Dunn, published in Bioorganic and Medicinal Chemistry, documented over 60 FDA-approved peptide drugs and more than 150 in active clinical development. What a local clinic markets as "peptide therapy" may or may not have any relationship to that clinical evidence base.

How Peptide Therapy Works: The Class-Level Biology

Receptor specificity and why it matters for provider evaluation

Peptide therapies work by binding to specific cell-surface receptors — triggering downstream signaling cascades that produce targeted physiological effects. A 2022 review by Wang and colleagues, published in Signal Transduction and Targeted Therapy, surveyed the therapeutic peptide field — current applications, production and modification technologies, and clinical pipeline across metabolic disease, oncology, and endocrinology. That specificity is what allows GLP-1 receptor agonists to stimulate insulin release only at elevated glucose levels — a pharmacological property that is entirely dependent on which receptor the compound binds. It is also why two compounds both marketed as "peptide therapy" can have completely different mechanisms, evidence bases, and risk profiles. A provider who cannot explain what receptor a compound targets, and what the clinical evidence shows for that mechanism, is not in a position to evaluate candidacy competently.

GLP-1 receptor agonists: the evidence anchor for metabolic peptides

Among peptide therapies for metabolic purposes, the GLP-1 receptor agonist class has the most extensive phase 3 clinical trial program to date — semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro). The STEP 1 trial, published by Wilding and colleagues in the New England Journal of Medicine in 2021, enrolled 1,961 adults and reported that weekly subcutaneous semaglutide 2.4 mg was associated with a mean body weight reduction of 14.9% versus 2.4% with placebo at 68 weeks in the trial population; 86.4% of semaglutide recipients lost at least 5% of body weight under study conditions. Individual outcomes vary and depend on clinical context. The SELECT trial, published by Lincoff and colleagues in 2023, reported that, among 17,604 adults with overweight or obesity without diabetes, semaglutide was associated with a 20% relative reduction in major adverse cardiovascular events (HR 0.80) versus placebo over the trial period. In SURMOUNT-1, published by Jastreboff and colleagues in 2022, tirzepatide 15 mg was associated with approximately 21% mean body weight reduction versus approximately 3% with placebo in the trial population of 2,539 adults without diabetes. A provider offering semaglutide or tirzepatide should be prescribing based on this evidence standard.

Growth hormone secretagogues: sermorelin and CJC-1295/ipamorelin

Growth hormone secretagogues stimulate the pituitary gland to produce endogenous GH in pulsatile patterns. Sermorelin is among the most frequently compounded GHRH-class peptides available through licensed U.S. pharmacies. A 1998 study by Raun and colleagues, published in the European Journal of Endocrinology, characterized ipamorelin as the first selective GH secretagogue without significant cortisol or ACTH elevation — the foundational mechanistic basis for the CJC-1295/ipamorelin combination. The clinical evidence for GH secretagogue use in adults without documented GH deficiency for body composition purposes is less robust than the GLP-1 class; adequately powered Phase 3 trials in this population are not available. Any off-label use reflects the independent clinical judgment of the prescribing physician.

Emerging evidence and honest expectations for local clinic offerings

A 2026 narrative review by Mayfield and colleagues, published in the American Journal of Sports Medicine, examined injectable peptides (including BPC-157, TB-500, CJC-1295/ipamorelin, tesamorelin, and GHK-Cu) in orthopaedic practice and concluded that significant research is still required before definitive recommendations can be made for most of these compounds. A companion review by Rahman and colleagues, published in the Journal of the American Academy of Orthopaedic Surgeons Global Research and Reviews in 2026, noted the absence of robust clinical trial data despite promising preclinical findings. Local clinics offering these compounds should be making these evidence gaps explicit to patients — not marketing them with implied clinical equivalence to FDA-approved compounds.

Who Is a Candidate for Peptide Therapy?

Who providers typically evaluate for this therapy

Candidacy depends on which compound class is under consideration. Providers evaluate candidacy based on clinical criteria, not self-reported interest.

• GLP-1 receptor agonists: Adults with BMI of 30 or greater, or BMI of 27 or greater with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea) — consistent with STEP and SURMOUNT trial enrollment criteria and FDA approved-indication labels.
• Growth hormone secretagogues: Adults with documented below-normal or low-normal IGF-1 levels associated with symptoms such as fatigue, reduced lean mass, and increased visceral adiposity, evaluated after other causes have been excluded.
• Tesamorelin (FDA-approved form only): HIV-positive adults with lipodystrophy. Off-label use for visceral fat reduction in other populations requires independent clinical judgment and has not been FDA-evaluated for those populations.

Candidacy assessment requires a full health history review, current medication list, and relevant baseline labs. Superpower's provider network evaluates candidacy and supervises access through licensed healthcare providers.

Who should not use this therapy

Based on compound-specific mechanisms, the following groups face elevated risk or are typically excluded from peptide therapy. This is not an exhaustive list; a licensed provider evaluates individual risk factors before prescribing.

• Active or suspected malignancy: Growth-promoting peptide pathways carry theoretical concern for proliferative stimulation; requires careful provider assessment case by case.
• Pregnancy and breastfeeding: No adequate safety data exist for most peptide therapies in these populations. GLP-1 receptor agonists should be discontinued before planned pregnancy per FDA labeling.
• Personal or family history of medullary thyroid carcinoma or MEN2: GLP-1 agonist FDA labeling carries a boxed warning for risk of thyroid C-cell tumors (based on rodent carcinogenicity studies) and contraindicates use in patients with a personal or family history of MTC or MEN2.
• Severe pancreatitis history: GLP-1 agonists carry a pancreatitis risk signal warranting careful provider assessment.
• Any individual considering unregulated gray-market sources: Products sold outside licensed pharmacy channels carry contamination and dosing risks that cannot be mitigated by the end user.

Why Pharmacy Sourcing Is a Clinical Quality Signal

What makes a compounding pharmacy legitimate

For compounded injectable peptides, the quality of the compounding pharmacy is a direct patient safety issue. The distinction matters because injectable compounds that are contaminated or incorrectly dosed cannot be identified by the patient and carry risks that do not exist with FDA-approved pharmaceutical products. A 2013 review by Gudeman and colleagues, published in Drugs in R&D, reviewed evidence that compounded drugs lack FDA premarket approval and that historical compounding quality failures have produced documented contamination events at higher rates than in FDA-approved manufacturing. The 2012 NECC meningitis outbreak — which resulted in more than 60 deaths from a contaminated steroid injection produced by an unaccredited pharmacy — is the most cited instance of compounding failure at scale. A 2013 analysis by Staes and colleagues in the American Journal of Health-System Pharmacy documented 11 infectious outbreaks from compounding pharmacies between 2000 and 2012, affecting 207 patients with 17 deaths, establishing the pattern before the NECC event. A 2013 commentary by Guharoy and colleagues in Chest framed the compounding pharmacy conundrum pragmatically: compounded preparations fill legitimate clinical gaps, but the oversight framework requires that pharmacies operating in this space meet rigorous standards. A 503A-licensed, USP-compliant pharmacy with state board inspection history is not equivalent to an unaccredited operation.

What to ask about pharmacy sourcing

Any provider offering compounded injectable peptides should be able to answer the following without hesitation: the name of their compounding pharmacy; confirmation that the pharmacy holds a valid state pharmacy license; confirmation that the pharmacy complies with USP <797> sterile compounding standards; and ideally, the name of the accreditation body. A provider who cannot or will not provide this information does not meet a reasonable clinical standard for sourcing transparency. The 2019 review by Mohiuddin, published in Innovations in Pharmacy, explained the legal and practice framework for 503A extemporaneous compounding, including the patient-specific prescription requirement — which means a legitimate compounding pharmacy should only be dispensing based on an individual patient prescription, not bulk dispensing without clinical evaluation.

The risk of gray-market injectable peptides

A significant portion of injectable peptides reaching consumers in the U.S. arrive through online vendors operating outside the licensed pharmacy framework — labeled "for research use only" and not subject to pharmaceutical-grade manufacturing standards. Case reports illustrate the clinical risk. Peters and colleagues, writing in CEN Case Reports in 2020, documented a case of renal infarction attributed to self-administration of online-purchased Melanotan II — a commonly advertised tanning peptide with no FDA approval. Cardones and Grichnik, writing in Archives of Dermatology in 2009, described eruptive melanocytic nevi with atypical clinical and histologic features in a 40-year-old patient with prior melanoma who used synthetic alpha-MSH peptides (melanotan) — a temporal association, not an established causal link. These are individual cases, not population-level incidence data, but they illustrate that the risks associated with unregulated injectable peptides are not theoretical. A 2026 narrative review by Mendias and Awan, published in Sports Medicine, noted that unapproved peptides marketed to patients have scarce human safety data and potential for serious harm — an assessment from researchers reviewing this space in 2026, not a historical precaution.

Delivery Methods for Peptide Therapy

Subcutaneous injection

Most compounded therapeutic peptides are administered by subcutaneous injection — into the fatty tissue just below the skin surface. This route provides consistent absorption and preserves peptide structural integrity better than oral delivery. Providers or their clinical staff guide technique at the first use. In the STEP 1 trial, participants self-administered weekly subcutaneous semaglutide at home following instruction; mean body weight reduction in the trial population was 14.9% at 68 weeks. At-home subcutaneous injection is feasible when performed according to provider instruction; individual outcomes vary.

Oral formulations

Oral semaglutide (Rybelsus) is FDA-approved for type 2 diabetes; it achieves oral bioavailability through a SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) permeation enhancer, as documented in a 2022 review by Aroda and colleagues in Reviews in Endocrine and Metabolic Disorders, characterizing the pharmacokinetics of the first orally administered GLP-1 receptor agonist. Most compounded peptides are not bioavailable orally and require injection. Oral peptide supplements sold through unregulated channels should not be assumed to deliver systemic pharmacological effects.

Nasal spray

A subset of providers offers intranasal compounded peptide formulations. Nasal delivery bypasses first-pass hepatic metabolism but produces more variable absorption than subcutaneous injection for most peptide classes. Clinical evidence for intranasal formulations of most growth hormone secretagogues and metabolic peptides is limited. Intranasal PT-141 (bremelanotide) was historically studied for sexual dysfunction applications; the FDA-approved bremelanotide product (Vyleesi) is an injectable indicated for premenopausal hypoactive sexual desire disorder, not an intranasal formulation. Most peptides have primary clinical data from injected routes.

Topical and other routes

Topical peptide preparations (creams, serums) are cosmetic products, not drugs. They are regulated under FDA cosmetics law and have not been evaluated for systemic therapeutic effects. Intravenous peptide infusion (used for select compounds in supervised settings) is not a self-administered route for standard peptide therapy protocols.

Safety and Side Effects

Side effect profiles vary significantly across the peptide therapy category. FDA-approved compounds have well-characterized safety data from large-scale human trials. Compounded formulations carry the same mechanism-based risks as the underlying compound, with additional manufacturing-quality considerations. Research-grade compounds sourced from unregulated channels carry unknown risk profiles.

Common side effects (mechanism-based, dose-dependent):

• Nausea, vomiting, diarrhea, and constipation — most common with GLP-1 receptor agonists during dose escalation; typically manageable and self-limiting over 4 to 8 weeks
• Injection site reactions (redness, bruising, mild swelling) — common with any subcutaneous injectable, typically self-limiting with proper site rotation
• Headache or mild fatigue, particularly in the first 1 to 2 weeks of therapy
• Reduced appetite — a mechanism-based effect with GLP-1 agonists; relevant for monitoring nutritional adequacy during weight-loss therapy

Less common but clinically important:

• Cholelithiasis — a meta-analysis by He and colleagues, published in JAMA Internal Medicine in 2022, found GLP-1 receptor agonists associated with increased gallbladder and biliary disease risk across 76 randomized controlled trials; a further meta-analysis by Chiang and colleagues in Gastroenterology in 2025 reported that GLP-1 agonist use was associated with increased gallstone and GERD risk across 55 RCTs
• Lean mass loss — a 2024 review by Locatelli and colleagues, published in Diabetes Care, reported that incretin-based therapy was associated with meaningful lean mass reduction and recommended supervised resistance exercise and monitoring
• IGF-1 elevation requiring monitoring — associated with growth hormone secretagogue therapy; baseline and follow-up IGF-1 testing is standard
• Impaired glucose tolerance — potential with GH-stimulating peptides; fasting glucose monitoring during GH-secretagogue therapy is standard practice

When to contact your provider:

• Persistent injection site pain, warmth, spreading redness, or fever
• Severe or persistent abdominal pain (potential pancreatitis signal with GLP-1 therapy)
• Cardiovascular symptoms — chest pain, shortness of breath, palpitations
• Signs of hypoglycemia in patients with metabolic conditions

What to Test Before Starting Peptide Therapy

A provider who does not require baseline testing before prescribing injectable peptides is operating below the clinical standard. Baseline labs are not optional — they are the reference data that make any subsequent change in your biology interpretable, and they establish the safety context the provider needs to prescribe responsibly.

• IGF-1: The primary baseline marker for anyone starting a growth hormone secretagogue. Monitoring IGF-1 at baseline establishes GH-axis status and is the reference for dose adjustment during therapy.
• Fasting glucose: Core metabolic marker. Baseline fasting glucose characterizes pre-treatment insulin sensitivity and enables interpretation of any glycemic changes during therapy.
• HbA1c: Three-month blood glucose average. The primary endpoint in semaglutide and tirzepatide clinical trials. A baseline HbA1c is essential for GLP-1 agonist therapy and relevant for GH-secretagogue therapy.
• Fasting insulin: Together with glucose, characterizes insulin resistance. Relevant before GLP-1 agonist or GH-secretagogue therapy. Baseline fasting insulin establishes the degree of insulin sensitivity before intervention.
• Lipid panel (triglycerides, LDL, HDL): Relevant for GLP-1 therapy given cholelithiasis risk and expected lipid effects. Baseline triglycerides and full lipid panel support interpretation of any subsequent changes.
• eGFR and creatinine: Renal clearance affects pharmacokinetics of injectable peptides. An eGFR baseline is part of standard pre-treatment safety assessment for injectable compound protocols.
• Liver enzymes (GGT, ALT): Hepatic function baseline. Changes in ALT and GGT can reflect hepatocellular response to therapy — both a safety and potential efficacy signal for compounds affecting visceral fat.
• hs-CRP: Systemic inflammation marker. Baseline hs-CRP provides context for peptides studied in anti-inflammatory or tissue-repair applications.

The metabolic health biomarker testing guide covers the core baseline markers in detail for anyone preparing for a provider consultation.

What Your Labs May Show During Peptide Therapy

Providers monitor specific biomarkers to assess whether therapy is producing its intended effect and to identify adverse signals early. For GLP-1 receptor agonist therapy, data consistent with therapeutic response include decreasing HbA1c and fasting glucose, improving lipid parameters, and — in high-risk patients — cardiovascular markers trending toward target. A real-world evidence review by Thomsen and colleagues, published in Diabetes, Obesity and Metabolism in 2025, documented real-world GLP-1 RA utilization patterns and discontinuation rates, noting that ongoing monitoring and clinical follow-up are associated with differences in adherence in the populations studied. For growth hormone secretagogue therapy, IGF-1 trending toward the age-appropriate reference range reflects pituitary response; fasting glucose is monitored for GH-related insulin sensitivity changes.

That principle — objective data before any clinical decision, and ongoing data to interpret response — is central to Superpower's approach to preventive health. The value of any peptide therapy experience is shaped in large part by the quality of the clinical oversight surrounding it.

Regulatory Status and How to Access Peptide Therapy

FDA approval status

As of April 2026, FDA-approved peptide medications in the categories most commonly sought through local clinic or telehealth searches include semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), tesamorelin (Egrifta), bremelanotide — marketed as Vyleesi and approved for hypoactive sexual desire disorder in premenopausal women — and insulin formulations. Details on semaglutide and tirzepatide are covered on their individual compound pages. Following the February 2026 FDA determination, BPC-157 and TB-500 are not eligible for 503A compounding; no lawful U.S. compounding pathway currently exists for these compounds. Local clinics offering these compounds as of April 2026 are operating outside the permissible compounding framework and should be disclosing this status to patients.

Compounding access and 503A

As of April 2026, sermorelin, CJC-1295 (without DAC), and ipamorelin remain available through licensed 503A compounding pharmacies for individual patient-specific prescriptions as Category 1 bulk substances. The FDA shortages for semaglutide and tirzepatide have been resolved and the corresponding 503A/503B compounding transition periods have elapsed. Under Section 503A's "essentially a copy" restriction (21 U.S.C. § 353a(b)(1)(D)), large-scale compounding of copies of FDA-approved semaglutide or tirzepatide is not permitted. Patient-specific compounding may remain lawful only where a prescriber documents a clinical difference meaningful to an identified patient — a narrow exception, not a general access pathway. Branded FDA-approved products remain available through licensed prescribers. Tesamorelin (Egrifta, an FDA-approved peptide drug) is not on the FDA's Section 503A bulk drug substances list and cannot be lawfully compounded under 503A; compounding copies of FDA-approved Egrifta is additionally barred by the "essentially a copy" restriction at 21 U.S.C. § 353a(b)(1)(D).

Cost and insurance framing

FDA-approved peptide medications for their approved indications may qualify for insurance coverage with prior authorization; actual coverage depends on the insurer's formulary and clinical documentation requirements. Off-label and compounded formulations are typically not covered. HSA and FSA accounts generally cover prescribed peptide therapy and telehealth consultation fees. No specific pricing claim across the category is reliable, as compound costs vary substantially by formulation, dosage, and compounding pharmacy. The evaluation process through a licensed provider includes a clinical consultation and baseline lab work before any prescription is issued.

How to Evaluate a Peptide Therapy Provider

The difference between a supervised clinical approach and unmonitored peptide access is the provider's clinical standards — not the format (in-person versus telehealth). A qualified peptide provider should offer clinical evaluation before prescribing, require relevant baseline labs, have a defined monitoring plan, and source compounds exclusively through state-licensed 503A compounding pharmacies compliant with USP <797>. The 2026 review by Mendias and Awan found that unapproved peptides entering the direct-to-consumer market have scarce human safety data and potential for serious harm — concerns that both the compounds themselves and the unregulated distribution framework contribute to.

Questions to ask before starting with any provider:

• Do you require baseline lab work before prescribing? Which specific markers do you assess for this compound?
• How will you monitor my response during therapy, and how often will labs be reviewed?
• Which compounding pharmacy do you use, and is it licensed and USP-compliant?
• Is this compound FDA-approved for the indication you are prescribing it for, or is it off-label? What is its current regulatory status?
• What is your plan if I experience side effects, or if I want to discontinue?
• How do you determine dosing, and how is it adjusted based on lab results?

Superpower's provider network evaluates candidacy and supervises access through licensed healthcare providers; baseline biomarker data — either from existing Superpower panels or new labs — is reviewed before prescribing. For evaluation and candidacy assessment through supervised clinical access, check eligibility for peptide therapy consultation. Prescribing decisions are made by licensed providers based on individual clinical evaluation, including baseline lab work. Where sermorelin is prescribed through Superpower's provider network, it is compounded from sermorelin acetate (currently classified as Category 1 under FDA's Interim Policy on bulk drug substances, making it eligible for 503A compounding while under review) at a state-licensed 503A pharmacy against a patient-specific prescription. No FDA-approved sermorelin product is currently marketed in the U.S.; 503A compounding is the only U.S. access pathway.

Superpower's peptide prescribing programs have state-level availability limitations. Tirzepatide prescribing is not available in New York, New Jersey, California, South Carolina, Alabama, Arkansas, or Louisiana. Sermorelin and other compounded peptide availability varies by state and should be confirmed during consultation.

IMPORTANT SAFETY INFORMATION

This article discusses peptide therapy access and provider evaluation across multiple compound categories, including both FDA-approved medications and compounds not FDA-approved for human use. Superpower Health does not prescribe medications. Superpower connects members with licensed healthcare providers who evaluate candidacy and prescribe where clinically appropriate.

As of April 2026, FDA-approved peptide medications including semaglutide and tirzepatide are available through licensed prescribers for approved indications. Compounded sermorelin, CJC-1295 (without DAC), and ipamorelin are available through licensed 503A compounding pharmacies with a patient-specific prescription. Following the February 2026 FDA determination, BPC-157 and TB-500 are not eligible for 503A compounding; no lawful U.S. compounding pathway currently exists for these compounds. Products sold through unregulated online channels labeled "for research use only" are not manufactured to pharmaceutical standards and carry contamination, dosing, and identification risks.

This content is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. Individual health conditions, current medications, and organ function affect both suitability and response to any peptide compound. For information about FDA-approved peptide medications, visit dailymed.nlm.nih.gov.

Disclaimer: This page discusses multiple compounds with varying FDA approval statuses. Some compounds mentioned may not be FDA-approved for human use. Superpower Health offers some but not all compounds discussed. See individual compound pages for specific availability and regulatory status. This content is for educational and informational purposes only.